A detailed history of West End Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, West End Advisors, LLC holds 52 shares of ABBV stock, worth $9,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52
Previous 54 3.7%
Holding current value
$9,360
Previous $9,000 11.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$163.84 - $199.33 $327 - $398
-2 Reduced 3.7%
52 $10,000
Q2 2024

Jul 29, 2024

SELL
$154.79 - $180.76 $1,083 - $1,265
-7 Reduced 11.48%
54 $9,000
Q1 2024

May 07, 2024

SELL
$159.82 - $182.1 $72,238 - $82,309
-452 Reduced 88.11%
61 $11,000
Q4 2023

Jan 18, 2024

SELL
$137.6 - $154.97 $17.6 Million - $19.8 Million
-127,663 Reduced 99.6%
513 $79,000
Q3 2023

Oct 19, 2023

BUY
$133.59 - $154.65 $3.94 Million - $4.56 Million
29,506 Added 29.9%
128,176 $19.1 Million
Q2 2023

Jul 21, 2023

SELL
$132.51 - $164.9 $1.19 Million - $1.48 Million
-8,975 Reduced 8.34%
98,670 $13.3 Million
Q1 2023

Apr 28, 2023

SELL
$144.61 - $166.54 $800,271 - $921,632
-5,534 Reduced 4.89%
107,645 $17.2 Million
Q4 2022

Jan 31, 2023

BUY
$138.31 - $165.87 $323,368 - $387,804
2,338 Added 2.11%
113,179 $18.3 Million
Q3 2022

Oct 27, 2022

SELL
$134.21 - $153.93 $1.48 Million - $1.7 Million
-11,043 Reduced 9.06%
110,841 $14.9 Million
Q2 2022

Jul 28, 2022

BUY
$137.62 - $174.96 $16.8 Million - $21.3 Million
121,867 Added 716864.69%
121,884 $18.7 Billion
Q1 2022

Apr 26, 2022

BUY
$131.98 - $163.75 $527 - $655
4 Added 30.77%
17 $2.76 Million
Q3 2021

Oct 26, 2021

SELL
$106.4 - $120.78 $106 - $120
-1 Reduced 7.14%
13 $1.4 Million
Q2 2021

Jul 15, 2021

BUY
$105.21 - $117.21 $1,472 - $1,640
14 New
14 $1.58 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track West End Advisors, LLC Portfolio

Follow West End Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of West End Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on West End Advisors, LLC with notifications on news.